Tzield Approval Expands to Younger Patients - Top-Institutions - MDSpire

Tzield Approval Expands to Younger Patients

First disease-modifying option available for children as young as 1 year with stage 2 type 1 diabetes

  • By

  • Kathryn Wighton

  • April 22, 2026

  • 2 min

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    Benaroya Research Institute at Virginia Mason
    Benaroya Research Institute at Virginia Mason

    Seattle, WA

    Key Differentiators

    • Immunology
    • Type 1 Diabetes Research
    • Pediatric Endocrinology

  • #2

    Barbara Davis Center for Diabetes, University of Colorado
    Barbara Davis Center for Diabetes, University of Colorado

    Aurora, CO

    Key Differentiators

    • Diabetes Research
    • Pediatric Endocrinology
    • Immunotherapy

  • #3

    Massachusetts General Hospital Diabetes Center
    Massachusetts General Hospital Diabetes Center

    Boston, MA

    Key Differentiators

    • Endocrinology
    • Immunology
    • Type 1 Diabetes

  • #4

    Yale Diabetes Center
    Yale Diabetes Center

    New Haven, CT

    Key Differentiators

    • Endocrinology
    • Immunology
    • Pediatric Diabetes

  • #5

    University of Florida Diabetes Institute
    University of Florida Diabetes Institute

    Gainesville, FL

    Key Differentiators

    • Diabetes Research
    • Pediatric Endocrinology
    • Immunotherapy

Original Source(s)

Tzield Approval Expands to Younger Patients

  • by Kathryn Wighton

  • April 22, 2026

Related Content

Feasibility and implementation of a daily safety brief at a children's hospital-in-a-hospital

Sex Disparities May Persist in CF Despite Modulators

Review findings suggested female patients with cystic fibrosis may continue to experience worse pulmonary outcomes despite highly effective modulator therapy

Can Digital Tools Fix Bias in Mental Health Triage?